Xiya Reagent:disposal of the older prescription drugs was one of

he disposal of the older prescription drugs was one of several moves by Britain's biggest drugmaker to improve its long-term growth profile and reduce complexity.

Some analysts, however, had questioned the timing of the sale since GSK is struggling with stagnant overall sales, putting pressure on its dividend, and divesting the mature drugs would have hit earnings in the short term.

A number of large drugmakers have weighed similar plans to hive off older products, with mixed results. Sanofi ditched the idea of selling its mature drugs this year after the idea was opposed by the board, an episode that contributed to the downfall of its CEO.

The drugs that GSK put on the block, known as established products, are expected to have combined 2014 sales of around 1 billion pounds($1.6 billion) but their sales are in long-term decline due to competition from cheaper generics.

They included antidepressant Paxil, migraine treatment Imitrex, Zantac for stomach acid and Zofran for nausea. The company always intended to retain the rights to such products in emerging markets, where they are still growing.

GSK Chief Executive Andrew Witty, who plans to close a major asset-swap deal with Novartis next year, is under pressure to deliver value to investors after a period of lacklustre performance.

He put a floor under the company's dividend in October by pegging the 2015 payout to the 2014 level and aims to save 1 billion pounds in annual costs over three years, resulting in job losses.· 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询